Heidelberg Pharma AG (LON: 0QW5)

Market Cap	97.75M
Revenue (ttm)	7.13M
Net Income (ttm)	-15.80M
Shares Out	n/a
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	800
Average Volume	60
Open	2.570
Previous Close	2.550
Day's Range	2.570 - 2.570
52-Week Range	1.748 - 3.065
Beta	-0.28
RSI	54.03
Earnings Date	Mar 24, 2025

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors. It i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 95
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QW5

Financial Performance

In 2023, Heidelberg Pharma AG's revenue was 9.86 million, a decrease of -46.75% compared to the previous year's 18.51 million. Losses were -20.35 million, 3.27% more than in 2022.

Financial numbers in EUR